An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Seattle Genetics, Inc
Start Date
September 25, 2020
End Date
October 19, 2025
Administered By
Duke Cancer Institute
Awarded By
Seattle Genetics, Inc
Start Date
September 25, 2020
End Date
October 19, 2025